Prostate cancer cell lines that can undergo epithelial-mesenchymal transition to investigate metastatic biomarkers or screen therapeutics.
- Two genetically similar, but characteristically distinct prostate cancer cell lines that are either resistant or prone to metastasis.
- Mouse models injected with ARCaPE developed bone metastasis in 12.5% of mice, whereas those injected with ARCaPM all developed bone metastasis.
The migration and invasiveness of metastasized cancer is thought to involve the epithelial-mesenchymal transition (EMT). Dr. Wu and colleagues have developed two prostate cancer cell lines from the androgen refractory cancer of the prostate (ARCaP) cell lineage that mimic EMT progression. The ACRaP epithelial (ARCaPE) and ACRaP mesenchymal (ARCaPM) cells are lineage related, but exhibit distinct characteristics. ARCaPE cells are held tightly together and have low metastatic potential, whereas ARCaPM cells are fibroblastic and are prone to spreading to soft tissues like bone. The switch between ARCaP epithelial to mesenchymal gene expression and morphology can shed light into the factors responsible for controlling metastasis. These cell lines can be used to investigate metastatic biomarkers and to screen through therapeutics ablating metastasis in cancer cells.
Cell lines are available for licensing.
Xu et al., Prostate. (2006) 66: 166-167.
Zhang et al., Oncogene. (2011) 30: 4941-4952.